Detection infrastructure is accelerating
Blood biomarkers, seed-amplification assays, subtype models, and enrichment endpoints are making separate neurodegenerative diseases easier to compare.
Neurology
Zemi Dossier
Research-use only
Neurodegeneration Convergence
A decision package on why shared neurodegeneration detection does not imply shared treatment strategy across Alzheimer’s, Parkinson’s, ALS, and related disorders.
Decision this dossier helps answer
Which neurodegeneration programs are using convergence for detection while still measuring the divergent biology needed for treatment decisions?
Problem this dossier solves
Detection is converging faster than treatment strategy.
Blood biomarkers, seed-amplification assays, AI subtyping, glial-state markers, and regulatory endpoint movement are making Alzheimer’s, Parkinson’s, ALS, and related disorders easier to compare. The buyer risk is treating shared detection as shared therapeutic logic. This decision package asks which biological state changes the sign of an intervention before a buyer funds a program, selects an endpoint, or runs the next study.
What is moving: biomarker and subtype infrastructure
What is unresolved: sign-labile treatment biology
What Zemi solves: evidence-gated next-study strategy
Full decision package
119-page research report plus 39-sheet Evidence & Decision Workbook
Buy now
$3,500$5,500Launch price
Controlling thesis
Converge to detect; diverge to treat.
The dossier argues that neurodegenerative diseases can share detection signals while requiring sharply different intervention logic. The decision package focuses on sign-labile glial state, resilience, subtype, and timing gates that determine whether the same target class heals or harms.
As of June 2026, the field is moving quickly toward blood-based detection, seed-amplification readouts, AI-assisted subtype classification, glial-state biology, and cross-diagnostic enrichment. That progress is useful, but it does not answer the hard buyer question: which convergent signal is merely a detection layer, and which divergent biological state makes a treatment testable?
The field's trap is treating convergence as one disease-modification thesis. This Zemi Dossier treats convergence as the detection layer, then asks which sign-labile state must be measured before an intervention is funded, built, avoided, monitored, or tested next.
Research report preview
First 30 pages of the actual Neurodegeneration Convergence research report.
The public page should let buyers inspect the real document style, density, evidence posture, and decision framing before they request access to the full Zemi Dossier package.
Evidence & Decision Workbook
The workbook is the decision engine.
A compact public preview of selected workbook-derived sheets: power calculations, next-study logic, sign-lability scoring, and traceability. Licensed buyers receive the full workbook files.
Read-only workbook preview from selected Neuro workbook rows. Licensed buyers receive the full 39-sheet Evidence & Decision Workbook with formulas, assumptions, and editable working files.
Report value
The research report frames the problem before it offers hypotheses.
The PDF research report is the structured argument: field status, evidence maturity, buyer implications, falsifiable hypotheses, power-calculated next studies, strategic recommendations, limitations, and traceability posture.
Shared detection can misroute treatment decisions
Biomarker movement is not disease modification. The same node may help or harm depending on glial state, disease context, subtype, and therapeutic window.
Turn convergence into testable strategy
The report converts a fast-moving evidence base into a sign-lability model, falsifiable hypotheses, next-study gates, and workbook-backed execution logic.
| Report layer | What it contains | Buyer value |
|---|---|---|
| Decision brief and scope | Evidence window, research-use boundary, buyer question, and what the dossier is not claiming. | Sets the credibility frame before the buyer reads technical claims. |
| Current field state | June 2026 biomarker, trial, regulatory, AI-subtyping, glial-state, and cross-diagnostic signals. | Shows why the opportunity is timely without implying the thesis is already proven. |
| Convergence-divergence model | Five coupled gates and the sign-lability logic used to separate detection convergence from treatment divergence. | Gives the buyer a reusable way to compare programs and avoid uniform-mechanism overfunding. |
| Evidence maturity and traceability | Known, inferred, and hypothetical claims; source quality; support verdicts; and explicit limitations. | Lets the buyer audit where the argument is strong, directional, or still hypothesis-generating. |
| Hypotheses and next studies | 15 falsifiable hypotheses, 8 next-study blueprints, endpoint logic, disconfirming tests, and study priorities. | Turns the field review into a testable action map rather than a narrative literature summary. |
| Limits and release discipline | Biomarker-not-modification boundary, early evidence posture, classifier limits, and release-audit governance. | Protects the buyer from over-reading a frontier strategy product as clinical guidance or peer review. |
Research report table of contents
Public TOC generated from the source report.
The full research report is delivered as a licensed PDF. This table shows the decision structure without publishing the full product.
| Section | What it covers | Buyer value |
|---|---|---|
| Executive Summary | Condenses the dossier thesis, evidence posture, buyer implications, and next-study priorities. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Scope & Evidence-Integrity Statement | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Lets the buyer audit support strength before relying on the package. |
| Decision Brief: Read This First | Turns the report into immediate buyer triage: what matters now, what is still uncertain, and what to do next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Outside in Landscape 2026 | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Decision Snapshot | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Cheat Sheet | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Source Quality Dashboard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Lets the buyer audit support strength before relying on the package. |
| The Convergence–Divergence Cascade & the Sign-Lability Law | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Convergence-Divergence Cascade - five coupled gates, and the law that makes it generative | Defines the governing argument and the evidence gates that would support or falsify it. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| The Sign-Lability Law | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The corollary - the aggregate is the scar; the wound is sign-labile | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| The Discovery Engine — A Quantitative Index, a Novel Assay, and a Bifurcation Theorem | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| The Sign-Lability Classifier — A Reusable, Executable Decision Model | Defines the governing argument and the evidence gates that would support or falsify it. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| 2025–2026 Current Signal Update → 2026–2028 Outlook | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Current-Signal Refresh — 2026 Frontier Readouts, Independently Verified | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross-Gate & Cross-Disease Convergence Map | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Cross-Domain Synthesis — Non-Obvious Claims | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Lets the buyer audit support strength before relying on the package. |
| Evidence Maturity & Comparative Mechanism/Subtype Matrix | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Key Findings | Summarizes the most decision-relevant findings and their implications for the dossier thesis. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Gate 2 - Sign-labile hub | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 5 - Detect/treat split | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 5 - Blood detection | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 4 - Strain x state subtype | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 3 - Resilience/progression | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 1 - IDP/condensate | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 2 - Cross-seeding | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 4 - APOE endotype | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 4 - AI classification | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 5 - Anti-amyloid RWD | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Gate 5 - Window staging | Defines the governing argument and the evidence gates that would support or falsify it. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Cross-gate - Evidence integrity | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Quantitative Evidence | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Lets the buyer audit support strength before relying on the package. |
| Mechanistic Deep-Dive | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Mechanistic System Dynamics - Bistability, Hysteresis & the Timing of Intervention | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Quantitative Cross-Cohort Synthesis | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Disease-Specific Translational Implications (AD · PD · ALS · FTD/DLB) | Identifies translational, regulatory, safety, or delivery constraints that shape whether the thesis can be tested. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
Evidence & Decision Workbook
The workbook is the trust engine and execution layer.
The Evidence & Decision Workbook exposes the claim, evidence, hypothesis, power, audit, and decision surfaces that make the dossier inspectable and reusable.
TraceabilityClaim Ledger, Evidence Table, Source-Support Verdicts, Source Quality Summary, Verification & Search Log, and Traceability Certificate make claims inspectable.
Evidence discipline585 verified identifiers and 419 adjudicated claims, including 332 excluded-claim dispositions so weak material does not leak into the buyer-facing thesis.
Decision modelThe 9-sheet Sign-Lability Classifier turns glial state, proteinopathy context, subtype, and timing into a research-use decision surface.
Power and execution15 hypothesis-linked power rows connect endpoint logic, assumptions, sample-size planning, sensitivity checks, budget, and timeline fields.
Next studies8 prioritized study blueprints specify the experiments most likely to confirm, weaken, or break the dossier thesis.
Field monitoringGate, biomarker, subtype, glial-state, therapeutic, regulatory, competitive, and failure-mode trackers help buyers monitor the domain after purchase.
Workbook inventory
Delivered workbook sheets.
Full inventories belong on dossier pages, not the homepage. Sheet names below are extracted from the actual workbook file.
| # | Workbook sheet | What it does |
|---|---|---|
| 1 | Workbook Guide | Navigation layer for using the workbook, understanding sheet roles, and following the decision package. |
| 2 | Claim Ledger | Claim-by-claim ledger showing verdicts, source support, inference status, and decision relevance. |
| 3 | Evidence Table | Evidence-verification surface for checking sources, support quality, and the audit trail. |
| 4 | Independent Source-Support Verd | Independent check on whether key claims are actually supported by cited sources. |
| 5 | Source Quality Summary | Summary of source strength, gaps, and areas where conclusions depend on weaker evidence. |
| 6 | Cascade-Gate Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| 7 | Disease-Mechanism Matrix | Comparison surface for separating shared mechanisms from domain-specific divergence. |
| 8 | Comparative Mechanism Matrix | Comparison surface for separating shared mechanisms from domain-specific divergence. |
| 9 | Biomarker Tracker | Tracks biomarkers or readouts that determine whether the thesis is moving toward testable evidence. |
| 10 | Subtype & Endotype Tracker | Segments the field by relevant biology so buyer decisions are not overgeneralized. |
| 11 | Phase-Separation IDP Tracker | Segments the field by relevant biology so buyer decisions are not overgeneralized. |
| 12 | Glial-State Tracker | Segments the field by relevant biology so buyer decisions are not overgeneralized. |
| 13 | Resilience Tracker | Segments the field by relevant biology so buyer decisions are not overgeneralized. |
| 14 | Therapeutic & Trial Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. |
| 15 | Failure-Mode Tracker | Captures failure modes and constraints that could invalidate or narrow a program. |
| 16 | Regulatory Tracker | Tracks regulatory, endpoint, reimbursement, or qualification requirements that shape testing strategy. |
| 17 | Hypotheses Ledger | Maps hypotheses to evidence state, falsification logic, endpoints, and next-study design. |
| 18 | Most Valuable Next Studies | Prioritizes next studies that could change the decision, including endpoints and evidence gates. |
| 19 | Validation Falsification Gates | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| 20 | Figure Source Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. |
| 21 | Figure Attempt Ledger | Figure and numeric reproduction log for validating calculations, chart inputs, or displayed values. |
| 22 | Verification & Search Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. |
| 23 | Excluded Claims (332) | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. |
| 24 | Salvage Ledger | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. |
| 25 | 28. Power Calculations | Power-calculation layer for assumptions, endpoint logic, computed sample sizes, and sensitivity checks. |
| 26 | 29. Score Basis | Explains how scores or ratings were assigned so the decision instrument can be inspected. |
| 27 | 30. Competitive Landscape | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. |
| 28 | 31. Traceability Certificate | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. |
| 29 | SLC_Input_Template | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| 30 | SLC_Feature_Score | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| 31 | SLC_Class_Output | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| 32 | SLC_Decision_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| 33 | SLC_Context_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| 34 | SLC_Minimum_Assay_Panel | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| 35 | SLC_Archetype_Cards | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| 36 | SLC_Validation_Log | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| 37 | SLC_Traceability_Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. |
| 38 | Version Registry | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. |
| 39 | Audit Issues Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. |
Decision instrument
Sign-Lability Classifier
This module converts the research thesis into a reusable, research-use decision surface inside the Evidence & Decision Workbook.
| Workbook sheet | Use |
|---|---|
| SLC_Class_Output | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| SLC_Decision_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| SLC_Context_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| SLC_Archetype_Cards | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| SLC_Validation_Log | Executable decision surface for classifying programs, risks, gates, or evidence states. |
| SLC_Traceability_Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. |
Power-calculated next studies
Power calculations are the execution bridge.
The Evidence & Decision Workbook carries 15 hypothesis-linked power rows. The interactive workbook simulation above shows how the live workbook surface behaves; the summary below shows a selected subset of endpoint logic, formula profile, and design n without publishing the full workbook.
| Hypothesis | Primary endpoint | Test | Effect | α | Power | Computed n | Design n |
|---|---|---|---|---|---|---|---|
| H12 | Treatment-by-triad interaction on disease-specific progression compos... | Two-proportion | 0.5 | 0.05 | 0.80 | 93 | 260 |
| H2 | DGAT2 treatment-by-stratum interaction on 18-mo NfL/clinical slope (o... | Two-sample t | 0.45 | 0.05 | 0.80 | 78 | 90 |
| H4 | Progression-PRS x treatment interaction on CDR-SB slope | Two-sample t | 0.4 | 0.05 | 0.80 | 99 | 110 |
| H5 | SPP1-lowering vs SPP1-raising TREM2 engagement, 12-18 mo NfL/GFAP slope | Two-sample t | 0.55 | 0.05 | 0.80 | 52 | 60 |
| H14 | Anti-amyloid CDR-SB slope: p-tau217-high/eMTBR-tau243-low vs tangle-h... | Two-sample t | 0.5 | 0.05 | 0.80 | 63 | 70 |
Release audit discipline
Audit posture is part of the product.
Public pages do not publish exact audit scores. They should state the release discipline, revision posture, and limitations without implying peer review or validated clinical guidance.
Research-use decision package
Not medical advice, clinical guidance, investment advice, or a clinical protocol.
Known / inferred / hypothetical
The package separates cited evidence from inference and frontier hypothesis generation.
Audit-gated and revision-controlled
Adversarial audit checks source support, formulas, figures, limitations, and release readiness.
Buy this dossier
Full decision package — 119-page report + 39-sheet workbook
Buy now
- Decision research report (119 pages, PDF)
- Evidence & Decision Workbook (39 sheets, .xlsx) — claims, source-support verdicts, power calculations, traceability, and audit log
- Live, editable power-calculated next studies
$3,500$5,500Launch price